COEP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 May 2024 @ 16:00):

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer...

Stats
Today's Volume	174 216
Average Volume	271 118
Market Cap	12.85M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.430
ATR14	$0.00500 (1.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-10	Cogley Brian	Buy	5 000	Common Stock
2024-01-10	Cogley Brian	Sell	0	Common Stock
2024-01-12	Desilva Tara	Buy	1 800	Common Stock
2024-01-12	Desilva Tara	Buy	466	Common Stock
2024-01-05	Yerace Daniel Alexander	Buy	10 850	Common Stock

INSIDER POWER
66.58
Last 46 transactions
Buy: 10 280 996 \| Sell: 12 141 291

Volume Correlation

Long: -0.30 (neutral)

Short: -0.43 (neutral)

Signal:(49.492) Neutral

Coeptis Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Coeptis Therapeutics, Correlation - Currency/Commodity

0.42
( neutral )

0.40
( neutral )

0.00
( neutral )

-0.38
( neutral )

Coeptis Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.830

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.830

FY	2022
Revenue:	$0
Gross Profit:	$-1.00M (0.00 %)
EPS:	$-2.87

FY	2021
Revenue:	$75 000.00
Gross Profit:	$75 000.00 (100.00 %)
EPS:	$-0.689

Financial Reports:

No articles found.

Coeptis Therapeutics,

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.